ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2805

Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls

Noha Elemam1, Mahmood Hachim 1, Suad Hannawi 2 and Azzam Maghazachi 1, 1Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, Sharjah, United Arab Emirates, 2Ministry of Health and Prevention-UAE, Department of Rheumatology, Dubai, United Arab Emirates

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Gene Expression and biomarkers, natural killer (NK) cells, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T110: Innate Immunity (2804–2809)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune diseases (1-3% of the world’s population). RA is a prototypic inflammatory disease, being characterized by an altered state of homeostasis, in which immunological stimulation and unwanted inflammation prevail (Pincus, Brooks et al. 1994). The molecular triggers for the development of RA in healthy subjects are still not clearly defined. Identification of RA specific transcriptional signature can shed the light on the molecular pathogenesis of RA. Such signature facilitates the selection of biomarkers that can be used for early detection of RA and prediction of effectiveness of RA treatment. Most of the current transcriptome analyses in RA had focused on whole peripheral blood mononuclear cells (PBMCs). Few studies have indicated that natural killer (NK) cells may play either a pathogenic or a protective role in RA (Shegarfi, Naddafi et al. 2012, Yap, Tee et al. 2018). Hence, in this study we aimed at exploring NK cell markers that could possibly be used to aid in evaluating the differences among healthy controls and RA patients.

Methods: Publicly available transcriptome dataset (GSE93777) of sorted immune cells from RA patients and healthy volunteers were reanalyzed using in house pipeline for normalization and filtration of the raw probes’ expression. Gene Set Enrichment analysis was used to identify genes that are differentially expressed (DEG) between different immune cells as compared to NK cells. Next, DEG between NK cells of RA patients and healthy controls were selected. Both lists of identified DEG were validated in peripheral blood collected from healthy controls and RA patients. Whole blood samples were collected from the recruited 11 RA patients (satisfying the 2010 ACR/EULAR classification criteria for RA) and 10 healthy controls (with no diagnosis of autoimmune diseases). Then, PBMCs were separated by Ficoll density gradient method, while NK cells were isolated using RosetteSep negative selection method. RNA was extracted and gene expression was assessed using qRT-PCR. Statistical analysis was done using Mann-Whitney test. Binary regression test was used to predict the probabilities of being a case based on the values of the selected genes.

Results: Similar to CD56, a known marker for NK cells, and interferon gamma (IFN-γ), a prototype cytokine secreted by these cells, PECAM-1, IBTK, ITGB7, and RELA were expressed in  NK cells (Figure 1A). Furthermore, chemokine ligands and receptors (CCR4, CXCL10, CXCL16, CXCR1, CXCR2, CXCR6) were specifically expressed by NK cells in comparison to PBMCs (Figure 1B). Additionally, as predicted by bioinformatics (Figure 2A), CXCL16, CD56, PECAM-1, ITGB7, BTK, TLR10, and IL-1β were significantly upregulated in NK cells of RA patients when compared to healthy controls, whereas CCL2 was downregulated (Figure 2B). In this study, we applied a logistic regression model using some of the identified NK genes expression (RELA, BTK, IL-1β, CKLF, PECAM-1, TLR10, IL1RN, IFN-γ) where it showed a good prediction power as predictors for RA.

Conclusion: Gene expression of these molecules; namely CXCL16, CD56, PECAM-1, ITGB7, BTK, TLR10 and IL-1β, in NK cells might be used as promising biomarkers for RA disease.

Figure 1. Differentially expressed genes -A- and chemokine ligands/receptors -B- between PBMCs and NK cells.

Figure 2. -A- In silico Gene Set Enrichment Analysis identified DEG between NK cells of RA patients and healthy controls. -B- Ex-vivo validation showed that NK cells from recruited RA patients showed differential expression of the predicted genes compared to healthy individuals.


Disclosure: N. Elemam, None; M. Hachim, None; S. Hannawi, None; A. Maghazachi, None.

To cite this abstract in AMA style:

Elemam N, Hachim M, Hannawi S, Maghazachi A. Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/natural-killer-cells-gene-expression-can-differentiate-rheumatoid-arthritis-patients-from-healthy-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/natural-killer-cells-gene-expression-can-differentiate-rheumatoid-arthritis-patients-from-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology